Major readouts on the horizon for small developers
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Covid vaccine development could go Omicron-and-on
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?